MedTrace Logo

An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193

NCT01933763 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2015-03-13

No results posted yet for this study

Summary

Study to assess the safety and tolerability of ascending single-doses of REGN1193 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

REGN1193

OTHER

Placebo

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01933763 on ClinicalTrials.gov